Background: The cysteinyl-leukotriene receptor type 1 (CysLT1) mediates the bronchoconstrictor and pro-inflammatory actions of cysteinyl-leukotrienes (LTC4, LTD4, LTE4) in asthma and is the molecular target of the lukast class of oral anti-leukotriene drugs. We screened the CYSLTR1 gene on chromosome Xq13-21 for coding region polymorphisms, and investigated their associations with allergy and asthma.
Methods: Solid-phase chemical cleavage was used to screen polymorphisms in the coding region of CYSLTR1. A TaqMan allelic discrimination assay was used to genotype a 927T/C SNP and oligonucleotide ligation assays were used to genotype the previously reported 617T/C and 898G/A SNPs of CYSLTR1 in 341 asthmatic families from the UK. Associations with asthma diagnosis, atopic status, serum-specific IgE and severity of allergy and asthma were examined.
Results: Family-based association tests showed that the 927 T allele was associated with atopy severity, especially in female subjects, but not with asthma diagnosis or severity, atopic status, bronchial hyper-responsiveness to methacholine or forced expiratory volume in 1 s.
Conclusion: Mutation screening identified only one polymorphism, 927T/C, in the coding region of the CysLT1 receptor. This polymorphsim is predictive of atopy severity, but not associated with asthma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-2222.2006.02511.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Demographics and clinical features of pediatric patients with allergic rhinitis: a single-center study from Western Turkey.
BMC Pediatr
March 2025
Department of Child Health and Diseases, Division of Pediatric Allergy and Immunology, Dokuz Eylul University Faculty of Medicine Hospital, Mithatpaşa Street, Number: 1606, Inciraltı, İzmir, Balçova, Turkey.
Background: Allergic rhinitis (AR) is a disease that has significant effects on the quality of life of people and exhibits different phenotypic features with different clinical findings. By analyzing the data of pediatric patients, we aimed to reveal the relationship between demographic and laboratory data and clinical features and to gain awareness about allergic rhinitis phenotypes in children.
Methods: Demographic data, clinical complaints, physical examination findings, and atopy biomarkers are retrospectively analyzed to assess the impact of aeroallergens on the disease phenotype.
[Guidelines for the prevention and management of bronchial asthma (2024 edition)].
Zhonghua Jie He He Hu Xi Za Zhi
March 2025
Bronchial asthma (asthma) is a common chronic respiratory disease. Standardized diagnosis, treatment and effective clinical management are critical to improving asthma control, improving patients' quality of life, and reducing the disease burden. Based on the latest evidence-based research from both domestic and international references, the Asthma Group of the Chinese Thoracic Society has revised the " ()".
View Article and Find Full Text PDFEffect of Supplementation with a Specific Probiotic ( PRL2010) in Pregnancy for the Prevention of Atopic Dermatitis in Children: Preliminary Results of a Randomized Trial.
Nutrients
February 2025
Department of Maternal, Infantile and Urological Sciences, Sapienza University of Rome, 00161 Rome, Italy.
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by the appearance of recurrent eczematous lesions and intense itching. The World Allergy Organization (WAO) suggested the administration of probiotics in pregnant women at high risk of allergies in their children.
Objectives: Our study aims to evaluate the role of administering the strain PRL2010 during pregnancy and breastfeeding in preventing and/or reducing the severity of AD manifestations in children.
Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment.
Int J Mol Sci
February 2025
Department of Translational Medical Sciences, University of Naples Federico II, 80131 Naples, Italy.
Severe asthma (SA) is a chronic inflammatory condition affecting approximately 10% of asthmatic patients, and eosinophils are considered key pathogenetic actors in a significant number of patients. Biological therapies have been demonstrated to improve asthma control by decreasing exacerbation rates and reducing the use of oral corticosteroids. In this context, phenotyping and endotyping patients with SA is essential for selecting the most effective therapeutic approach.
View Article and Find Full Text PDFElevated mepolizumab levels in patients with severe asthma responsive to 1 year's mepolizumab treatment.
J Allergy Clin Immunol Glob
May 2025
Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan.
Background: Asthma involves variable airflow limitation and persistent airway inflammation. Eosinophilic asthma, characterized by cytokine-mediated type 2 inflammation, is generally treated with inhaled corticosteroids. However, patients with severe asthma may require biologics, such as mepolizumab, which targets IL-5 and can manage uncontrolled eosinophilic asthma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!